StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
STTKBullishEarningsnews
High materiality8/10

Shattuck Labs reports strong SL-325 Phase 1 data; Crohn's 2b on track and cash runway to 2029

Aug 11, 2026, 6:18 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Clinical milestones (Phase 2b initiation, data readouts) and a strengthened balance sheet reduce execution risk and extend runway, potentially supporting a re-rating of STTK as pipeline progress compounds with capital efficiency.

AI summary

What happened, with direct paths to the underlying reporting

Shattuck Labs reports Phase 1 SL-325 data showing favorable safety and durable TL1A-DR3 blockade, with a Q3 2026 start planned for RECEPTIVE-CD1 Phase 2b in Crohn's disease. The company also advances SL-846 with an IND-enabling program and a 2027 data readout, while maintaining a robust cash runway into 2029, collectively signaling potential near-term clinical catalysts and longer-term growth optionality in the DR3 axis.

  • Phase 1 SL-325 shows favorable safety and durable TL1A-DR3 blockade.
  • Antidrug antibodies detected in 3.7% of participants.
  • RECEPTIVE-CD1 Phase 2b Crohn's trial to start in Q3 2026.
  • SL-846 bispecific; initial data expected in 2027.
  • Cash and equivalents reach $208.3M as of 6/30/2026; runway to 2029.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event